A u-shape association of serum uric acid with gout

2 in US adults

- 3 Yan Xinmiao¹, Sun Taolan¹, Zhao Zixuan¹, Luo Yanrong², Zhao Hanbing², Zhao Han², Li Miaojing^{2*}
- ⁴ ¹ Chengdu Medical College, Chengdu, Sichuan, 610500, PR China
- ² Department of health management, College of health and intelligent engineering, Chengdu,
- 6 Sichuan, 610500, PR China
- 7 *Corresponding author
- 8 E-mail: <u>limiaojing@aliyun.com</u> (LMJ)
- 9

10 Abstract

11 Background

Serum uric acid (SUA) level is the strongest determinant of gout, and the relationship between hyperuricemia and gout has been found. However, the association between the across-full range of SUA level and gout also remains uncertain. We aimed to investigate the trend across an across-full range of SUA level and gout in the general population.

17 Materials and Methods

This study included 4,738 US adults from The National Health and Nutrition
Examination Survey (NHANES). A generalized additive model was used to
fit the non-linear trend between SUA level and gout.

21 **Results**

2,209 males and 2,469 females were included in our study, with the age 22 range of 20~80 years. The range of SUA level was from 0.8 to 15.1 mg/dL. 23 About 5.9% of participants had gout. There was a U-shape association 24 between SUA level and gout in univariable GAM (EDF = 3.881, p < 0.001) 25 and multivariable GAM (EDF = 3.795, p < 0.001). The lowest risk of gout 26 was observed in participants with SUA level of 5-6mg/dL. We evaluated the 27 trend of SUA level with gout by gender. Both males and females with high 28 SUA level have a high prevalence of gout. Male have a high prevalence of 29 gout with low SUA level. The SUA level and prevalence of gout support a 30 U-shape in males, while females show a linear shape. 31

32 Conclusion

- 33 This study showed that low as well as high SUA are associated with gout.
- 34 Hypouricemia is a candidate predictor of gout in US adults.

35

37

38 Introduction

According to the Global Burden of Disease (GBD) 2017, there were 41.2 39 million (95% UI: 36.7 million~46.1 million) adults with gout worldwide. In 40 2017, the age standardized point prevalence estimate and the increase of 41 age-standardized point prevalence estimate of gout in the United States 42 ranked among the top three in the world[1]. A prospective cohort study 43 showed that the all-cause standardized mortality in gout patients was 2.21 44 (95% CI: 1.68-2.74)[2]. In addition, gout is associated with several diseases, 45 including joint pain, chronic kidney disease (CKD), hypertension, type 2 46 diabetes, dyslipidemia, etc[3], which has effect on the life [4], 47 productivity[5, 6] and health-related quality of life (HRQOL)[7, 8]. High 48 uric acid (hyperuricemia) is the strongest determinant of gout, and many 49 50 studies have proved the existence of this association [9-11]. SUA level can be maintained at a certain target level through urate-lowering treatment 51 (ULT), effectively reducing the incidence of gout[12, 13]. Although some 52 research on high SUA level and gout has been reported, the underlying 53 association between across-full range of SUA level and gout is still 54 uncertain. There is currently a lack of consensus regarding the optimal range 55 for SUA levels and few studies have evaluated the prevalence of gout across 56 the full range of SUA level in the US adults. 57

58 An analysis of the time of first gout occurrences using Cox proportional

hazards model in a cohort study in Japan showed that the HR of 59 asymptomatic hyperuricemia (5.0 < SUA \leq 6.0 mg/dL) of ULT was the 60 lowest, at 0.45 (95% CI: 0.27-0.76), compared with untreated subjects (SUA 61 > 8.0 mg/dL). In subjects with asymptomatic hyperuricemia, controlling 62 SUA can reduce or eliminate gout occurrences[14]. In another Mendelian 63 randomization study, it presented convincing evidence that the increased 64 risk of gout was associated with high SUA level (n=71 501, OR: 5.84; 95% 65 CI: 4.56-7.49, p < 0.01)[15]. Meanwhile, studies have shown that before the 66 age of 65 years, male have a fourfold greater incidence of gout than female 67 [10, 16-18]. However, the risk of gout development in patients with 68 hypouricemia has not yet been clarified. D'silva et al reported that the risk 69 70 of all-cause mortality risk among US males with SUA level <4 mg/dL was about 30% higher[19]. This indicates that it is necessary to further study 71 the relationship between SUA level and gout and its impact on males and 72 females. 73

Therefore, based on the National Health and Nutrition Examination Survey
(NHANES), we explore the trend between SUA level and gout.

76

77 Materials and methods

78

79 Data Source and Study Population

80 The National Health and Nutrition Examination Survey (NHANES) is a

unique source of national data on the health and nutritional status of the US population, collecting data through interviews, standard exams, and biospecimen collection. NHANES adopts a stratified and multi-stage sampling design, and the survey population involves each county in US. Each year, about 5,000 persons in 15 counties are selected to conduct a nationally representative sample survey. Informed consent was obtained from all participants.

88

NHANES 2017-2018 dataset was used in this study. There was a total of 90 9,254 participants being enrolled. Participants with age \geq 20 years old were 91 included for analysis. However, we excluded participants that had no uric 92 acid data (*n*=3353), no gout data(*n*=987), missing in covariates variables 93 (*n*=176). Eventually, 4,738 participants were included in our study and the 94 distribution of the number of participants with different value of uric acid 95 are shown in Fig 1.

96

Fig 1. Distribution of the number of participants with different value of uric acid.

99

100 Variable measurements

101 Socio-demographic factors and modifiable risk factor of gout were included102 in this study. We obtained the data of these variables from seven parts of

following: "Demographic Data", "Standard Biochemistry Profile",
"Alcohol Use", "Blood Pressure & Cholesterol", "Smoking - Cigarette Use",
"Kidney Conditions - Urology" and "Medical Conditions".

107 **Gout**

108 Gout was self-reported data. Whether participants have gout was defined
109 using the question, "Has a doctor or other health professional ever told you
110 that you had gout?".

111

Serum Uric acid level

In this study, we used the SUA level in the laboratory data as interested independent variable and recorded as a continuous variable. The detail process of laboratory data measurement was described in the NHANES database official website.

117

118 **Covariates**

In this study, the covariates included gender, age, education, marriage, race,
alcohol drinking, smoking, hypertension, diabetes and kidney disease. Age
was divided into three groups: 20~39, 40~59, and 60 years or older.
Education level was categorized into primary and secondary, high school,
above high school. Marriage was grouped into four categories: married,
widowed divorced or separated, never married, living with a partner. Race

was divided into six categories: Mexican American, other Hispanic, non-125 Hispanic White, non-Hispanic Black, non-Hispanic Asian, other race -126 127 including Multi-Racial. Alcohol drinking was classified as never, almost every day, 3 to 4 times a week, 1 to 2 times a week, 1 to 3 times a month, 128 and 1 to 11 times a year. Smoking was defined as "at least 100 cigarettes in 129 130 a lifetime". Diagnosis of hypertension, diabetes and kidney disease were determined with questions: "Have you ever been told by a doctor or health 131 care provider that you have high blood pressure, diabetes or problems with 132 high blood sugar, weak or failing kidneys". 133

134

135 Statistical Analysis

136 Descriptive statistics on participants' characteristics were stratified by whether they had gout. Chi-squared test was utilized to determine the 137 association between categorical variable. The generalized additive model 138 (GAM) was used to assess the potential trend between SUA level and gout. 139 The GAM approach is an extension of the generalized linear model (GLM), 140 which is a generalized linear model with linear predictions involving sums 141 of covariates (Wood, 2011). The smoothness of the model terms was 142 estimated using penalized cubic regression splines for fitting. The model 143 selection included the Akaike information criterion (AIC), the difference 144 between EDF and ref. df, with lower values considered to be better-fitting 145 models. As our response variable types were categorical variables, we chose 146

147	"Logit" as our link function, and it was considered that the fixed effects
148	were estimated by Restrictive maximum likelihood (REML).
149	(http://doi.org/10.1080/01621459.2016.1180986)
150	Non-linear relationship of SUA level with gout was assessed through GAM.
151	In our analysis, we fit three GAM models to NHANES data. The three
152	models used gout (yes/no) as a binary response.

153

	Response	Predictor
Model 1	Gout	Smooth (SUA level)
Model 2	Gout	Smooth (SUA level) +Covariates
Model 3	Gout (Group by Gender)	Smooth (SUA level) +Covariates

154

The reported values of effective degree of freedom (EDF) demonstrate the degree of curvature of the smooth. "EDF=1" means a linear pattern of the relationship. "EDF >1" is the sign of a more complex relationship between SUA level and gout. The Ref. df is close to the EDF when the GAM is reasonably fitted. The best explanation for the P-value of the smooth part is that a line parallel to the X-axis cannot pass through the 95% confidence interval of the curve.

SAS 9.4 (Statistical analysis system) was used for data cleaning and
statistical description. GAM in our analysis was using the "mgcv" package
(version 1.8–28) in R statistical software (version 4.1.1). The statistical
tests were two-sided, and the significance level was set at 0.05.

167 **Results**

168 Characteristics of participants

A total of 4,738 eligible participants (2,209 males and 2,469 females) were included in our study, with the age range of 20~80 years. About 48.12% were male, and 56.61% educated in above high school. A total of 50.65% of the sample were married. The range of SUA level was from 0.8 to 15.1 mg/dL. About 5.9% of participants had gout. All factors had significant statistical differences except education, details are shown in Table 1.

- 175

Table 1. characteristics of the participants in NHANES according to gout

	n (%)	Gout		Р
		Yes , <i>n</i> =280	No , <i>n</i> =4458	
Uric acid (mg/dL)		6.35±1.79	5.41±1.46	< 0.001
Gender				
Male	2280(48.12)	193(8.46)	2087(91.54)	< 0.001
Female	2458(51.88)	87(3.54)	2371(96.46)	
Age				
20-39years	1444(30.48)	13(0.90)	1431(99.10)	< 0.001
40-59years	1515(31.98)	74(4.88)	1441(95.12)	
Over 60 years	1779(37.55)	193(10.85)	1586(89.15)	
Education				
Primary and secondary	389(8.21)	20(5.14)	369(94.86)	0.780
High	1667(35.18)	98(5.88)	1569(94.12)	
Above high	2682(56.61)	162(6.04)	2520(93.96)	
Marital Status				
Married	2400(50.65)	153(6.38)	2247(93.63)	< 0.001

Widowed, Divorced or	1068(22.54)	84(7.87)	984(92.13)	
Separated				
Never married	845(17.83)	23(2.72)	822(97.28)	
Living with partner	425(8.97)	20(4.71)	405(95.29)	
Race				
Mexican American	651(13.74)	21(3.23)	630(96.77)	0.002
Other Hispanic	444(9.37)	16(3.60)	428(96.40)	
Non-Hispanic White	1656(34.95)	116(7.00)	1540(93.00)	
Non-Hispanic Black	1080(22.79)	67(6.20)	1013(93.80)	
Non-Hispanic Asian	670(14.14)	48(7.16)	622(92.84)	
Other Race - Including Multi-	237(5.00)	12(5.06)	225(94.94)	
Racial				
Alcohol				
Never drink	927(23.20)	73(7.87)	854(92.13)	0.001
Every day or almost every day	272(6.81)	25(9.19)	247(90.81)	
3-4 times a week	243(6.08)	18(7.41)	225(92.59)	
1-2 times a week	603(15.09)	34(5.64)	569(94.36)	
1-3 times a month	841(21.05)	39(4.64)	802(95.36)	
1-11 times last year	1110(27.78)	47(4.23)	1063(95.77)	
Diabetes				
Yes	737(15.56)	100(13.57)	637(86.43)	< 0.00
No	3853(81.32)	166(4.31)	3687(95.69)	
Borderline	148(3.12)	14(9.46)	134(90.54)	
Kidney disease				
Yes	188(3.97)	42(22.34)	146(77.66)	< 0.00
No	4550(96.03)	238(5.23)	4312(94.77)	
Hypertension				
Yes	1790(37.78)	185(10.34)	1605(89.66)	< 0.00
No	2948(62.22)	95(3.22)	2853(96.78)	

Smoking				
Yes	1967(41.52)	160(8.13)	1807(91.87)	< 0.001
No	2771(58.48)	120(4.33)	2651(95.67)	

176

177 Model 1: Gout and serum uric acid(univariable)

Model 1 used gout (Yes/No) as a binary response. The results of non-linear 178 parameters of GAM were presented in Table 2. A smoothing spline function 179 of SUA level as a univariable predictor was shown in Fig 2(EDF= 3.881,180 p < 0.001). The prevalence of gout increased with the increase of SUA level 181 at the SUA level of 5-10 mg/dL. When the SUA level was extreme, the trend 182 was relatively flat. 183 184 Fig 2. Figure of estimated smoothing spline function of prevalence of gout (The 185 reference group is participants without gout) with 95% confidence band for the 186

187 univariable generalized additive model 1.

188

189Table 2. the smooth function of gout measured by the GAM (model1)

Smooth terms	EDF	Ref.df	c^2	Р
Reference (Yes)				
Gout (No)	3.881	4.875	123.4	< 0.001

190

191 Model 2: Gout and serum uric acid(multivariable)

Model 2, which was a multivariable version of model 1 but further adjustedfor covariates was shown in Fig 3.A non-linear shape was found between

194	SUA level and gout (EDF=3.795, $p < 0.001$), and the predicted smooth
195	association of SUA level and gout including the 95% confidence intervals,
196	was shown in Fig 3. The figure showed a U-shape association of SUA level
197	and the prevalence of gout in multivariable GAM models. The lowest
198	prevalence observed was SUA level of 5-6mg/dL. SUA level had the
199	strongest effect on gout at the SUA level which was lower than 5 mg/dL or
200	at 6-11 mg/dL. While SUA level exceed 11 mg/dL, the prevalence of gout
201	began to decline slowly. The results of non-linear parameters of GAM were
202	presented in Table 3, the parameter section results were detailed in S1 Table.
203	
204	Fig 3. Figure of estimated smoothing spline function of prevalence of gout (The
205	reference group is participants without gout) with 95% confidence band for the
206	multivariable generalized additive model 2 adjusted for gender, age, marital
207	status, education, race, smoking, alcohol, diabetes, kidney disease and
208	hypertension.
209	

210 Table 3. the smooth function of gout measured by the GAM (model2) Smooth terms EDF Ref.df c^2 P Reference (Yes) Gout (No) 3.795 4.789 37.67 <0.001

211

212 Model 3: Gout and serum uric acid (Group by gender)

213	Furthermore, the effect of SUA level on gout in male and female was
214	evaluated in model 3. The significant result indicates a non-linear shape
215	between SUA level and gout in male ($EDF=1.873$, $p<0.001$), which was
216	similar to the trend of entire population. However, the non-linear shape
217	between SUA level and gout was not identified in female (EDF=1.001,
218	p=0.087). The Fig 4 showed the smoothing shapes are different in male and
219	female, which a significant U-shape association of SUA level and the gout
220	in male and a linear in female. The lowest risk is observed in those SUA
221	level 5~6mg/dL in male and low or high SUA level will increase the risk of
222	gout. The results of non-linear parameters of GAM were presented in Table
223	4, the parameter section results were detailed in S2.1 and S2.2 Table.
224	

Fig 4. Figures of estimated smoothing spline function of prevalence of gout level 225 (Group by gender, and the reference group is participants without gout) with 226 95% confidence band for the multivariable generalized additive model 3. And a 227 for male, b for female. 228

229

230

Table 4. Association of SUA level and gout measured by the GAM(Group

by gender)(model3)					
Smooth terms	EDF	Ref.df	c^2	Р	
Reference (Yes)					
Spline (Uric Acid): Male	1.873	1.984	16.45	< 0.001	
Spline (Uric Acid): Female	1.001	1.002	2.931	0.087	

232

233

234 **Discussion**

As the final product of purine metabolism, SUA has many effects on the human body. Previous studies found that increased SUA levels were associated with gout, diabetes[20], hypertension[21], obesity[22], and cancer[23, 24]. However, few studies have assessed the relationship between across-full range of SUA level and gout. This study constructs a generalized additivity model to explore the potential relationship between SUA level and gout based on US adults.

In our study, the *EDF* of univariate and multivariate models adjusted for 242 age, sex, education and other important confounding factors were all greater 243 244 than 3, indicating a non-linear relationship between SUA level and gout and a U-shape association was demonstrated in the figure. The results of our 245 study showed a high prevalence of gout with high SUA level in US adults, 246 but the prevalence of gout begins to decline slowly when SUA level is above 247 11 mg/dL. Males with low SUA level also have a high prevalence of gout. 248 The association between SUA level and prevalence of gout support a U-249 shape in males, while females show a linear shape. 250

A previous study already confirmed that SUA level higher than 6mg/dL can increase the risk of gout, which is in agreement with our result[25]. Secondly, the prevalence of gout decreased when SUA level was higher than 11 mg/dL. We speculated that the high level of SUA in this part of the

population may be caused by other diseases or drugs[26]. Furthermore, low 255 SUA level was also associated with gout. A sudden decrease in SUA may 256 also trigger a gout attack by dissolution of monosodium urate (MSU) from 257 tophi[26]. In addition, hypouricemia has been shown to increase the risk of 258 CARES 259 worsening kidney function. In the trial, all-cause and cardiovascular mortality rates were higher in the febuxostat group than in 260 the allopurinol group, despite lower SUA levels in gout patients taking 261 febuxostat[27]. Some previous studies also showed that SUA was u-shape 262 associated with all-cause mortality[28, 29] and nephropathy, and SUA 263 reduction treatment was associated with higher mortality[30].One study 264 showed that SUA level between 5-6mg/dL is reasonable[31], which is 265 266 consistent with our finding. Ames et al hypothesized that SUA may act as a protective factor against aging and cancer caused by oxidants and free 267 radicals due to its antioxidant function[32]. Therefore, SUA should be 268 maintained in a certain range, above or below this range will increase the 269 probability of developing gout. The different trends between males and 270 females are because estrogen has a urination effect on females, which can 271 reduce the risk of gout. However, with elevated SUA level after menopause, 272 the proportion of older female with gout may increase and gender 273 differences decrease[17, 33]. 274

275 Studies have shown that the occurrence of gout is related to kidney 276 disease[9, 34, 35]. SUA level in vivo is closely related to renal function.

About two-thirds of uric acid is excreted in urine[36], and uric acid is 277 filtered by glomerulus and reabsorbed by proximal tubules, with a normal 278 excretion rate of 10%[37]. A prospective cohort study showed a U-shape 279 association between SUA and loss of renal function in healthy subjects[38]. 280 Therefore, the relationship between SUA and kidney disease may be a 281 potential cause for the existence of this U-shape association that was found 282 in our study, but further studies are needed to prove this. Because gout is 283 considered a disease that primarily affects male, it may be underrecognized 284 in female even after menopause. There were clear differences in risk 285 between male and female. 286

There are also limitations in our research. Firstly, our research is an 287 288 observational study, which cannot infer a causal relationship between SUA level and gout. Secondly, many variables in our study are self-reported. 289 Despite these limitations, our study also has advantages. Firstly, this study 290 used a smoothing curve to explore the non-linear trend between SUA level 291 and gout. Secondly, we assessed the risk of gout at all SUA level in the 292 ordinary population, taking into account both low SUA level and high SUA 293 level. Finally, we assessed the trend of prevalence of gout with SUA level 294 in both males and females. 295

296

297 **Conclusion**

In our study, there is a U-shape between SUA level and gout. High SUA level or low SUA level are both risk factors for gout. Further researches are needed to trace people with low SUA level and clarify the pathophysiological mechanisms between low SUA level and gout to reduce the likelihood of gout occurring.

303

304 Author Contributions

305 YXM and STL were responsible for data extraction, data analyses, model 306 construction and the manuscript writing. LMJ selected the topic, directs the 307 writing, improves the revision. ZZX provided specific knowledge, carried 308 out the literature research. ZHB, ZH, LYR coordinated and managed the 309 operation of the project and the implementation of the project. All authors 310 read and approved the final manuscript.

311

313

References 314

315 1. Safiri S, Kolahi A-A, Cross M, Carson-Chahhoud K, Hoy D, Almasi-Hashiani A, et al. 316 Prevalence, Incidence, and Years Lived With Disability Due to Gout and Its Attributable Risk Factors 317 for 195 Countries and Territories 1990-2017: A Systematic Analysis of the Global Burden of Disease 318 Study 2017. Arthritis Rheumatol. 2020;72(11):1916-27. doi: 10.1002/art.41404. PubMed PMID: 319 32755051.

320 2. Disveld IJM, Zoakman S, Jansen TLTA, Rongen GA, Kienhorst LBE, Janssens HJEM, et al. 321 Crystal-proven gout patients have an increased mortality due to cardiovascular diseases, cancer, and 322 infectious diseases especially when having tophi and/or high serum uric acid levels: a prospective cohort 323 study. Clin Rheumatol. 2019;38(5):1385-91. doi: 10.1007/s10067-019-04520-6. PubMed PMID: 324 30929152.

325 3. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on 326 prevalence and treatment options. BMC Med. 2017;15(1):123. doi: 10.1186/s12916-017-0890-9. 327 PubMed PMID: 28669352.

328 4. Roddy E, Zhang W, Doherty M. Is gout associated with reduced quality of life? A case-control 329 study. Rheumatology (Oxford). 2007;46(9):1441-4. PubMed PMID: 17586863.

330 Edwards NL, Sundy JS, Forsythe A, Blume S, Pan F, Becker MA. Work productivity loss due 5 331 to flares in patients with chronic gout refractory to conventional therapy. J Med Econ. 2011;14(1):10-5. 332 doi: 10.3111/13696998.2010.540874. PubMed PMID: 21138339.

333 6 Kleinman NL, Brook RA, Patel PA, Melkonian AK, Brizee TJ, Smeeding JE, et al. The impact 334 of gout on work absence and productivity. Value Health. 2007;10(4):231-7. PubMed PMID: 17645677.

335 Khanna D, Ahmed M, Yontz D, Ginsburg SS, Park GS, Leonard A, et al. The disutility of 7 336 chronic gout. Qual Life Res. 2008;17(5):815-22. doi: 10.1007/s11136-008-9355-0. PubMed PMID: 337 18500578.

338 Singh JA. Racial and gender disparities among patients with gout. Curr Rheumatol Rep. 8. 339 2013;15(2):307. doi: 10.1007/s11926-012-0307-x. PubMed PMID: 23315156.

340 9. Kuo C-F, Grainge MJ, Zhang W, Doherty M. Global epidemiology of gout: prevalence, 341 incidence and risk factors. Nat Rev Rheumatol. 2015;11(11):649-62. doi: 10.1038/nrrheum.2015.91. 342 PubMed PMID: 26150127.

343 10. Richette P, Bardin T. Gout. Lancet. 2010;375(9711):318-28. doi: 10.1016/S0140-344 6736(09)60883-7. PubMed PMID: 19692116.

345 11. Dalbeth N, Gosling AL, Gaffo A, Abhishek A. Gout. Lancet. 2021;397(10287):1843-55. doi: 10.1016/S0140-6736(21)00569-9. PubMed PMID: 33798500. 346

347 12. Hainer BL, Matheson E, Wilkes RT. Diagnosis, treatment, and prevention of gout. Am Fam 348 Physician. 2014;90(12):831-6. PubMed PMID: 25591183.

349 13. Perez-Ruiz F. Treating to target: a strategy to cure gout. Rheumatology (Oxford). 2009;48 Suppl 2. doi: 10.1093/rheumatology/kep087. PubMed PMID: 19447780. 350

351 14. Koto R, Nakajima A, Horiuchi H, Yamanaka H. Serum uric acid control for prevention of gout 352 flare in patients with asymptomatic hyperuricaemia: a retrospective cohort study of health insurance 353 claims and medical check-up data in Japan. Ann Rheum Dis. 2021;80(11):1483-90. doi: 354 10.1136/annrheumdis-2021-220439. PubMed PMID: 34158371.

355

15. Keenan T, Zhao W, Rasheed A, Ho WK, Malik R, Felix JF, et al. Causal Assessment of Serum

Urate Levels in Cardiometabolic Diseases Through a Mendelian Randomization Study. J Am Coll
 Cardiol. 2016;67(4):407-16. doi: 10.1016/j.jacc.2015.10.086. PubMed PMID: 26821629.

Ruoff G, Edwards NL. Overview of Serum Uric Acid Treatment Targets in Gout: Why Less
Than 6 mg/dL? Postgrad Med. 2016;128(7):706-15. doi: 10.1080/00325481.2016.1221732. PubMed
PMID: 27558643.

361 17. Saag KG, Choi H. Epidemiology, risk factors, and lifestyle modifications for gout. Arthritis
362 Res Ther. 2006;8 Suppl 1:S2. PubMed PMID: 16820041.

363 18. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and
364 hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol.
365 2004;31(8):1582-7. PubMed PMID: 15290739.

D'Silva KM, Yokose C, Lu N, McCormick N, Lee H, Zhang Y, et al. Hypouricemia and
Mortality Risk in the US General Population. Arthritis Care Res (Hoboken). 2021;73(8):1171-9. doi:
10.1002/acr.24476. PubMed PMID: 33026684.

20. van der Schaft N, Brahimaj A, Wen K-X, Franco OH, Dehghan A. The association between
serum uric acid and the incidence of prediabetes and type 2 diabetes mellitus: The Rotterdam Study.
PLoS One. 2017;12(6):e0179482. doi: 10.1371/journal.pone.0179482. PubMed PMID: 28632742.

21. Zheng R, Yang T, Chen Q, Chen C, Mao Y. Serum Uric Acid Concentrations Can Predict
Hypertension: A Longitudinal Population-Based Epidemiological Study. Horm Metab Res.
2017;49(11):873-9. doi: 10.1055/s-0043-119129. PubMed PMID: 28922678.

22. Zheng R, Chen C, Yang T, Chen Q, Lu R, Mao Y. Serum Uric Acid Levels and the Risk of
Obesity: a Longitudinal Population-Based Epidemiological Study. Clin Lab. 2017;63(10):1581-7. doi:
10.7754/Clin.Lab.2017.170311. PubMed PMID: 29035437.

378 23. Yue C-F, Feng P-N, Yao Z-R, Yu X-G, Lin W-B, Qian Y-M, et al. High serum uric acid
379 concentration predicts poor survival in patients with breast cancer. Clin Chim Acta. 2017;473:160-5. doi:
380 10.1016/j.cca.2017.08.027. PubMed PMID: 28844462.

24. Shin H-S, Lee H-R, Lee D-C, Shim J-Y, Cho K-H, Suh S-Y. Uric acid as a prognostic factor
for survival time: a prospective cohort study of terminally ill cancer patients. J Pain Symptom Manage.
2006;31(6):493-501. PubMed PMID: 16793489.

25. Perez-Ruiz F, Dalbeth N, Bardin T. A review of uric acid, crystal deposition disease, and gout.
Adv Ther. 2015;32(1):31-41. doi: 10.1007/s12325-014-0175-z. PubMed PMID: 25533440.

26. Zhang W-Z. Why Does Hyperuricemia Not Necessarily Induce Gout? Biomolecules.
2021;11(2). doi: 10.3390/biom11020280. PubMed PMID: 33672821.

White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, et al. Cardiovascular
Safety of Febuxostat or Allopurinol in Patients with Gout. N Engl J Med. 2018;378(13):1200-10. doi:
10.1056/NEJMoa1710895. PubMed PMID: 29527974.

391 28. Hu L, Hu G, Xu BP, Zhu L, Zhou W, Wang T, et al. U-Shaped Association of Serum Uric
392 Acid With All-Cause and Cause-Specific Mortality in US Adults: A Cohort Study. J Clin Endocrinol
393 Metab. 2020;105(1). doi: 10.1210/clinem/dgz068. PubMed PMID: 31650159.


394 29. Stotz M, Szkandera J, Seidel J, Stojakovic T, Samonigg H, Reitz D, et al. Evaluation of uric
395 acid as a prognostic blood-based marker in a large cohort of pancreatic cancer patients. PLoS One.
396 2014;9(8):e104730. doi: 10.1371/journal.pone.0104730. PubMed PMID: 25133546.

30. Odden MC, Amadu A-R, Smit E, Lo L, Peralta CA. Uric acid levels, kidney function, and
cardiovascular mortality in US adults: National Health and Nutrition Examination Survey (NHANES)
1988-1994 and 1999-2002. Am J Kidney Dis. 2014;64(4):550-7. doi: 10.1053/j.ajkd.2014.04.024.


400 PubMed PMID: 24906981.

401 31. Bellomo G, Selvi A. Uric Acid: The Lower the Better? Contrib Nephrol. 2018;192:69-76. doi:
 402 10.1159/000484280. PubMed PMID: 29393097.


- 403 32. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in
 404 humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A.
 405 1981;78(11):6858-62. PubMed PMID: 6947260.
- 33. Doherty M. New insights into the epidemiology of gout. Rheumatology (Oxford). 2009;48
 Suppl 2:ii2-ii8. doi: 10.1093/rheumatology/kep086. PubMed PMID: 19447779.
- 408 34. Feig DI, Kang D-H, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med.
 409 2008;359(17):1811-21. doi: 10.1056/NEJMra0800885. PubMed PMID: 18946066.
- 35. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence,
 treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16(7):380-90. doi: 10.1038/s41584-0200441-1. PubMed PMID: 32541923.
- 413 36. Bobulescu IA, Moe OW. Renal transport of uric acid: evolving concepts and uncertainties.
 414 Adv Chronic Kidney Dis. 2012;19(6):358-71. doi: 10.1053/j.ackd.2012.07.009. PubMed PMID:
 415 23089270.
- 416 37. Fathallah-Shaykh SA, Cramer MT. Uric acid and the kidney. Pediatr Nephrol. 2014;29(6).
 417 doi: 10.1007/s00467-013-2549-x. PubMed PMID: 23824181.
- 418 38. Kanda E, Muneyuki T, Kanno Y, Suwa K, Nakajima K. Uric acid level has a U-shaped
 419 association with loss of kidney function in healthy people: a prospective cohort study. PLoS One.
 420 2015;10(2):e0118031. doi: 10.1371/journal.pone.0118031. PubMed PMID: 25658588.
- 421




Figure




Figure



Figure





Figure